{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=clinical+course&page=2", "query": { "intervention": "clinical course", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=clinical+course&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T07:55:21.570Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00678470", "title": "Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Moderate to Severe Psoriasis" ], "interventions": [ { "name": "Intralesional Alefacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2007-09", "completion_date": "2011-06", "has_results": true, "last_update_posted_date": "2019-04-18", "last_synced_at": "2026-09-24T07:55:21.570Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00678470" }, { "nct_id": "NCT04354701", "title": "COVID-19 and Cancer Consortium Registry", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "COVID-19", "Invasive Malignancy (Any Type)" ], "interventions": [ { "name": "Web-based REDCap survey", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19275, "start_date": "2020-03-17", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2024-01-09", "last_synced_at": "2026-09-24T07:55:21.570Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04354701" }, { "nct_id": "NCT00466687", "title": "Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "fluorescence in situ hybridization", "type": "GENETIC" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "GENETIC", "OTHER", "PROCEDURE" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2004-09", "completion_date": "2008-09", "has_results": true, "last_update_posted_date": "2013-07-22", "last_synced_at": "2026-09-24T07:55:21.570Z", "location_count": 4, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00466687" }, { "nct_id": "NCT05112432", "title": "EPI-MINN: Targeting Cognition and Motivation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Psychosis" ], "interventions": [ { "name": "Cognitive and Social Cognitive Training", "type": "DEVICE" }, { "name": "Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App", "type": "BEHAVIORAL" }, { "name": "Early Psychosis Coordinated Specialty Care", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "BEHAVIORAL", "OTHER" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "15 Years to 40 Years" }, "enrollment_count": 400, "start_date": "2021-08-12", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-09-24T07:55:21.570Z", "location_count": 3, "location_summary": "Duluth, Minnesota • Minneapolis, Minnesota", "locations": [ { "city": "Duluth", "state": "Minnesota" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05112432" }, { "nct_id": "NCT00245063", "title": "AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Non-small Cell Lung Cancer" ], "interventions": [ { "name": "cediranib maleate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacogenomic studies", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2006-03", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2014-10-02", "last_synced_at": "2026-09-24T07:55:21.570Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00245063" }, { "nct_id": "NCT05925322", "title": "Brain Changes During Social Reward Psychotherapy for Mid- and Late-Life Suicidality", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Depression", "Suicidal Ideation", "Major Depressive Disorder", "Depressive Disorder" ], "interventions": [ { "name": "\"Engage & Connect\" Psychotherapy", "type": "BEHAVIORAL" }, { "name": "Symptom Review and Psychoeducation (SRP)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 128, "start_date": "2023-09-18", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-09-24T07:55:21.570Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05925322" }, { "nct_id": "NCT05558475", "title": "The DigIT Trial: The Effectiveness and Implementation of a Coached Digital Insomnia Treatment Program in a Regional Healthcare System.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Insomnia Disorder" ], "interventions": [ { "name": "Virtual Coaching", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 244, "start_date": "2023-04-27", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2026-02-03", "last_synced_at": "2026-09-24T07:55:21.570Z", "location_count": 5, "location_summary": "West Haven, Connecticut • Augusta, Maine • Leeds, Massachusetts + 2 more", "locations": [ { "city": "West Haven", "state": "Connecticut" }, { "city": "Augusta", "state": "Maine" }, { "city": "Leeds", "state": "Massachusetts" }, { "city": "Manchester", "state": "New Hampshire" }, { "city": "White River Junction", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT05558475" }, { "nct_id": "NCT00729612", "title": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel albumin-stabilized nanoparticle formulation", "type": "DRUG" }, { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "immunoenzyme technique", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER" ], "sponsor": "Greg Otterson", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 63, "start_date": "2008-08-14", "completion_date": "2011-12-16", "has_results": true, "last_update_posted_date": "2018-04-02", "last_synced_at": "2026-09-24T07:55:21.570Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00729612" }, { "nct_id": "NCT05030051", "title": "A Proof of Concept Study to Evaluate the Efficacy and Tolerability of Skinpen on Male and Female Subjects' Dorsal Hands as a Treatment of Hand Aging", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Skin Aging" ], "interventions": [ { "name": "SkinPen Precision System", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Crown Laboratories, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "50 Years to 75 Years" }, "enrollment_count": 18, "start_date": "2021-03-12", "completion_date": "2022-11-30", "has_results": false, "last_update_posted_date": "2023-12-18", "last_synced_at": "2026-09-24T07:55:21.570Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05030051" }, { "nct_id": "NCT05877716", "title": "EPI-MINN: Targeting Cognition and Motivation - National", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Psychosis", "Psychosis Nos/Other", "Schizophrenia", "Schizo Affective Disorder", "Schizoaffective Disorder", "Prodromal Schizophrenia", "Schizophrenia Spectrum and Other Psychotic Disorders", "Schizophreniform Disorders", "Major Depression With Psychotic Features", "Unspecified Psychosis", "Bipolar Disorder" ], "interventions": [ { "name": "Cognitive and Social Cognitive Training", "type": "DEVICE" }, { "name": "Personalized Real-Time Intervention for Motivational Enhancement (PRIME) App", "type": "BEHAVIORAL" }, { "name": "Early Psychosis Coordinated Specialty Care", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "BEHAVIORAL", "OTHER" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "15 Years to 40 Years" }, "enrollment_count": 55, "start_date": "2023-05-30", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-09-24T07:55:21.570Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05877716" } ] }